Rilpivirine

Drug Profile

Rilpivirine

Alternative Names: Edurant; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rilpivirine hydrochloride; TMC 278; TMC278 LA (IM injection) - Tibotec; TMC278LA

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen Therapeutics; PATH
  • Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Apr 2016 Janssen completes a phase I trial in volunteers in Belgium (NCT2547870)
  • 01 Apr 2016 Janssen Sciences Ireland completes the phase I trial in Healthy volunteer in Belgium (NCT02561936)
  • 01 Jan 2016 Janssen completes a phase I trial for HIV-1 infections (Prevention) in USA (IM) (NCT01656018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top